Sensus Healthcare (SRTS) Expected to Release Earnings on Monday

Sensus Healthcare (NASDAQ:SRTS) is anticipated to announce its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect the company to announce earnings of ($0.1250) per share and revenue of $4.6010 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, May 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Sensus Healthcare had a negative net margin of 34.50% and a negative return on equity of 15.79%. The business had revenue of $3.39 million for the quarter, compared to analysts’ expectations of $5.32 million.

Sensus Healthcare Stock Up 0.7%

Shares of SRTS opened at $2.91 on Friday. The stock has a market cap of $47.90 million, a P/E ratio of -6.19 and a beta of 1.09. The business’s 50 day moving average price is $2.94 and its 200-day moving average price is $3.79. Sensus Healthcare has a 52 week low of $2.66 and a 52 week high of $5.92.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a research note on Friday, July 17th. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Finally, Wall Street Zen lowered Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $6.88.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new position in Sensus Healthcare during the fourth quarter valued at approximately $77,000. Jane Street Group LLC bought a new stake in Sensus Healthcare in the 4th quarter worth approximately $79,000. Ingalls & Snyder LLC bought a new stake in Sensus Healthcare in the 4th quarter worth approximately $219,000. State Street Corp raised its stake in Sensus Healthcare by 5.2% during the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock valued at $276,000 after buying an additional 3,400 shares during the last quarter. Finally, Rothschild Wealth LLC purchased a new stake in Sensus Healthcare during the 4th quarter valued at $500,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.